USG Cover Coat Joint Compound
Product Description
USG Cover Coat was a finishing-grade joint compound manufactured by United States Gypsum Company (USG), one of the dominant suppliers of gypsum-based building products in North America throughout the twentieth century. Produced from approximately 1964 through 1976, Cover Coat was formulated specifically as a topping or finish compound, intended for the final coats applied over taped drywall seams, corner beads, and fastener dimples before sanding and painting.
As a finish compound, Cover Coat was engineered to spread smoothly and sand easily — properties that made it attractive to drywall finishers and plasterers seeking a fine, paintable surface. It was sold in both dry powder form, which required mixing with water on the job site, and as a pre-mixed wet compound in buckets. The product was marketed to construction contractors, industrial facilities, commercial builders, and retail consumers during the period when asbestos-containing joint compounds were common throughout the building trades.
USG was, and remains, a major corporation with a long history in the manufacture of wallboard, plaster, and related finishing materials. The Cover Coat line represented one segment of the company’s broad joint compound portfolio during the 1960s and 1970s — a period when the use of chrysotile asbestos as a functional additive in building materials was widespread and largely unregulated at the federal level.
Asbestos Content
USG Cover Coat joint compound, as produced during the 1964–1976 manufacturing window, contained chrysotile asbestos as a component of its dry formula. Chrysotile, also called white asbestos, is a serpentine-form mineral fiber that was widely used in building products during this era because of its binding characteristics, tensile strength, and resistance to cracking during drying and curing.
In joint compound formulations, chrysotile served a practical function: the flexible, curly fibers helped reinforce the compound matrix, reducing shrinkage cracking and improving workability. These same physical properties — fine diameter, durability, and the tendency to separate into microscopic fibrils under mechanical stress — are what make chrysotile hazardous when disturbed.
Chrysotile asbestos is classified as a known human carcinogen by the International Agency for Research on Cancer (IARC) and is regulated as a hazardous material under OSHA’s asbestos standards (29 CFR 1910.1001 and 29 CFR 1926.1101). All commercial forms of asbestos, including chrysotile, are subject to AHERA (the Asbestos Hazard Emergency Response Act) provisions governing identification and management in built environments. No form of asbestos is considered safe at any level of occupational exposure under current regulatory standards.
How Workers Were Exposed
Exposure to asbestos fibers from USG Cover Coat joint compound occurred primarily through the mechanical disturbance of the dry or cured product. The nature of finish compound work made such disturbance routine and unavoidable.
Mixing: Workers who mixed dry-powder Cover Coat with water generated clouds of fine particulate dust, including liberated asbestos fibers. Pouring, scooping, and agitating the dry powder in buckets or on mechanical mixing paddles created an immediate inhalation hazard.
Application and finishing: Applying joint compound with knives and trowels over large wall and ceiling surfaces, particularly in enclosed rooms with limited ventilation, could generate airborne dust from product overspray and tool drag.
Sanding: The most significant exposure pathway documented in litigation records involves the dry sanding of cured joint compound. Finish compounds were specifically designed to sand easily — a property that also meant they abraded readily into fine dust. Hand sanding and power sanding of walls and ceilings coated with Cover Coat released asbestos fibers into the air in concentrations that could persist long after active work ceased, particularly in enclosed interior spaces.
Bystander and ambient exposure: Industrial workers generally present in facilities undergoing drywall installation or renovation — including maintenance personnel, supervisors, and workers in adjacent trades — could be exposed to asbestos-laden dust generated by others working with Cover Coat without themselves being directly involved in finishing work.
Because finish joint compounds were used during the final stages of interior construction, sanding typically occurred in nearly completed, enclosed spaces where airborne dust had limited means of escape and dilution. Workers in these environments often had no respiratory protection during the years this product was manufactured, as neither the hazard nor OSHA’s current asbestos permissible exposure limits (PEL) were consistently communicated or enforced.
Documented Trust Fund / Legal Options
USG Cover Coat is a Tier 2 — Litigated product. United States Gypsum Company has not established a dedicated asbestos bankruptcy trust fund. USG reorganized under Chapter 11 bankruptcy in 2001, with asbestos liability at the center of that proceeding, and emerged from bankruptcy in 2006 following the establishment of a trust under Section 524(g) of the Bankruptcy Code — the United States Gypsum Asbestos Personal Injury Settlement Trust. This trust was created to resolve present and future asbestos claims arising from USG products.
Individuals who were exposed to USG Cover Coat and subsequently diagnosed with an asbestos-related disease may have eligibility to file claims with the USG Asbestos Personal Injury Settlement Trust. Litigation records document claims brought by workers and their survivors alleging that exposure to USG joint compound products, including finishing compounds manufactured during the asbestos-content period, caused mesothelioma, lung cancer, asbestosis, and other asbestos-related conditions.
Plaintiffs alleged that United States Gypsum knew or should have known about the hazards associated with asbestos in its joint compound products and failed to adequately warn workers and consumers of the risks. Litigation records document arguments that the company’s failure to reformulate products or provide safety warnings during the period of known asbestos hazard contributed directly to occupational disease.
Potentially compensable disease categories in asbestos litigation and trust proceedings typically include:
- Mesothelioma (pleural, peritoneal, pericardial)
- Lung cancer with documented asbestos exposure history
- Asbestosis and diffuse pleural thickening
- Other asbestos-related pleural conditions
Claim eligibility, evidentiary requirements, and compensation values are determined by the trust’s trust distribution procedures (TDP) and may vary based on diagnosis, exposure documentation, and claim tier. Workers with documented exposure to USG Cover Coat between 1964 and 1976 — particularly those who mixed, applied, or sanded the product — as well as their surviving family members, should consult with a qualified asbestos attorney to evaluate available legal remedies.
Statutes of limitations apply to asbestos claims and vary by state. Early consultation with legal counsel experienced in asbestos litigation is strongly advised.